82745-18-4

Upstream product

• 75-04-7 ethylamine 
• 2493-02-9 4-bromophenyl isocyanate 
• 106-40-1 4-bromo-aniline 
• 109-90-0 ethyl isocyanate 

Downstream Products

• 861557-71-3 N-ethyl-N'-(4-bromo-2,6-dinitro-phenyl)-N-nitro-urea 
• 1345041-54-4 C₁₆H₂₁BrN₂O₃ 
• 874291-00-6 1-ethyl-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]urea 
• 62554-90-9 4-bromo-2,6-dinitroaniline 

Relevant academic research and scientific papers

Compound for inhibiting SREBP-1 target point and application thereof

The invention belongs to the technical field of pharmacy. Specifically, the invention provides a compound for inhibiting an SREBP-1 target, and an isomer, a pharmaceutically acceptable salt or a hydrate thereof. The invention aims to provide a compound fo

Pyrido-pyrimidines, its preparation and use

The invention discloses pyridopyrimidine compounds with a general formula (I), wherein Ar is aryl or heteroaryl; R1 is hydrogen, halogen, amino, heterocyclic group, alkyl, aminoalkyl, heterocyclic alkyl, aryl, heteroaryl, cyano, alkenyl or alkynyl; R2 is

Having a spiro ring substituent of aryl morpholine compound, its preparation and use

The invention discloses arylmorpholine compounds with spiro substituents. The arylmorpholine compounds are compounds having the following general formula (I), wherein X is N or CH; R1 is hydrogen, hydroxyl, alkoxy, halogen, amino, amido, acylamino, sulfam

As the PI3K/mTOR inhibitor tricyclic compound, its preparation and use

The invention discloses a tricyclic compound as a PI3K/mTOR inhibitor. The tricyclic compound is a compound with the general formula (I) in the specification, wherein Ar is selected from aryl or heteroaryl; X, Y and Z are independently selected from O, CR2R3 and NR4 respectively; Q is selected from O, CR2R3 and NR4 or does not exists; R1 represents C1-C6 alkyl; n is selected from integers from 0 to 4; when n is more than or equal to 2, two R1 and a morpholine cycle can be combined into a combined cycle, a bridge cycle or a spiral cycle; R2 and R3 are selected from hydrogen and C1-C6 alkyl; R4 is selected from hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, heterocyclic radical, acyl and sulfonyl. The invention further discloses a perpetration method of the compound with the general formula (I) as well as a pharmaceutical composition and application of the compound with the general formula (I).

Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases

Tetra-substituted imidazoles were designed as dual inhibitors of c-Jun N-terminal kinase (JNK) 3 and p38α mitogen-activated protein (MAP) kinase. A library of 45 derivatives was prepared and evaluated in a kinase activity assay for their ability to inhibi

PI3K/MTOR KINASE INHIBITORS

6-morpholin-4-yl-pyrazolo[3,4-d]pyrimidine and 2-morpholin-4-yl-7H- pyrrolo[2,3-d]pyrimidine derivatives have unexpected drug properties as inhibitors of PI3 and/or mTOR kinases and are useful in treating disorders related to abnormal PI3K/mT0R activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.